Viragen Files to Expand Cancer Approval for Multiferon in Sweden

Viragen and its majority-owned subsidiary, Viragen International, have announced that an application has been filed with the Swedish regulatory authorities seeking to expand the approval for Multiferon to include the first-line adjuvant treatment of high-risk malignant melanoma, following dacarbazine after surgical removal of tumors.

This submission represents the initial step of the company's plans to seek broader European approvals for Multiferon.